Palisade Bio Inc reports a Return on Equity (ROE) of -18.96%.

What is PALI's dividend yield?

Palisade Bio Inc offers a dividend yield of 0.00%.

What is PALI's Quality Score?

Our AI rates PALI's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PALI?

Our AI Timing Score for PALI is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PALI belong to?

Palisade Bio Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Palisade Bio Inc (PALI) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

PALI AI Analysis Summary

Our AI summary for PALI: Palisade Bio Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -18.96%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PALI

Palisade Bio Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 1.94

0.05 (2.37%) Day Change

Watchlist Portfolio Compare Chart

0.05

D/E

-19.0%

ROE

-18.1%

ROA

0.00%

Div Yield

PALISADE BIO INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.94 Price 0.05 (2.37%) Day Change	NEWS SCORE: 99

PALI, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.94
PBV / Sector	2.59 / 44,219.29
Earning Per Share	-0.14

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	5.39 M GREAT
Average 1W Daily Value	2.86 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	-5,312.00 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-18.12 / 185,260.96
ROA Average (%) / Sector	-68.26 / 36,684.70
ROA Change Average (%) / Sector	0.70 / 422,221.66
ROE (%) / Sector	-18.96 / 243,762.23
ROE Average (%) / Sector	-89.53 / 48,758.47
ROE Change Average (%) / Sector	6.33 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:58
Symbol	PALI
Name	PALISADE BIO INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	173.58 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	329.31 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 4600 South Syracuse Street, Denver, CO, United States, 80237

Phone: 858 704 4900

Website: https://www.palisadebio.com

Sector: Healthcare >> Biotechnology

Description: Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.